

# VolitionRx

09:32 10 Jul 2019

## VolitionRx Limited awarded an additional \$1.4 million in non-dilutive funding

VolitionRx Limited (NYSEAMERICAN:VNRX) revealed Wednesday that it has secured an additional \$1.4 million in non-dilutive funding in the form of a non-repayable cash grant from the Walloon Region in southern Belgium.

To date, agencies from Walloon have awarded the Isnes, Belgium-based life-sciences company nearly \$6 million in non-dilutive funding including the most recent award.

"It is a key part of our financing strategy to actively seek non-dilutive funding as this provides additional cash at favorable terms to support the company's continued development," said CEO Cameron Reynolds. "We are delighted with the great progress we are making on so many fronts and look forward to achieving many milestones throughout this year."

### BIG PICTURE: VolitionRx's Nu.Q cancer-screening blood tests could replace colonoscopies, biopsies

The company has designed routine Nu.Q blood-based diagnostic tests to screen for colorectal and prostate cancers that reduce the need for more invasive colonoscopies and biopsies. It might also work as a screening tool for endometriosis and has potential veterinary uses as well.

"We are delighted with the financial assistance that we have received from the Walloon Region and would like to thank Monsieur Pierre-Yves Jeholet, the Walloon Minister for Economy for his continued support," said Dr Gaetan Michel, CEO of Volition's subsidiary, Belgian Volition SPRL. "This grant will support a specific project to be conducted in collaboration with GIGA at the University of Liege, Belgium."

GIGA is the University of Liège's interdisciplinary research institute in the biomedical sciences.

The project led by Dr Denis Mottet, head of the Protein Signaling and Interaction Laboratory at GIGA, will explore the mechanisms of Telomers (protein-DNA complexes) maintenance, inherent to cancer cells, as a tool for cancer diagnostics using Volition's Nucleosomics platform.


Volition's NuQ platform looks for molecular signatures of cancer by focusing on the nucleosomes — a section of DNA wrapped around a core of proteins — in the blood. As cancer cells multiply, they are modified in a way that distinguishes them from healthy cells and the traits of the malignant disease appear on the nucleosomes, which are analyzed by Nu.Q's platform.

The company has already tested Nu.Q to detect prostate cancer. In August 2018 Volition announced preliminary data from an 84-patient study that showed its Nu.Q test kits diagnosed men with aggressive prostate cancer with 94% accuracy.

**Price:** 3.24

**Market Cap:** \$155.26 m

#### 1 Year Share Price Graph



October 2019    April 2020    October 2020

#### Share Information

**Code:** VNRX

**Listing:** NYSEMKT

<b>52 week</b>	<b>High</b>	<b>Low</b>
	6.11	2.22

**Sector:** Pharma & Biotech

**Website:** volitionrx.com

#### Company Synopsis:

*Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present. &nbsp;.*

action@proactiveinvestors.com

Volition's R&D activities are currently centered in Belgium, with additional offices in Texas, London and Singapore.

Contact Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: @UttaraProactive

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).